Evoke Pharma (EVOK) Revenue & Revenue Breakdown
Evoke Pharma Revenue Highlights
Latest Revenue (Y)
$5.18M
Latest Revenue (Q)
$1.74M
Evoke Pharma Revenue by Period
Evoke Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $5.18M | 106.51% |
| 2022-12-31 | $2.51M | 55.04% |
| 2021-12-31 | $1.62M | 6929.00% |
| 2020-12-31 | $23.02K | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | - |
Evoke Pharma generated $5.18M in revenue during NA 2023, up 106.51% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Evoke Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.74M | 3.55% |
| 2023-12-31 | $1.68M | 7.24% |
| 2023-09-30 | $1.56M | 38.14% |
| 2023-06-30 | $1.13M | 39.60% |
| 2023-03-31 | $810.41K | 1.76% |
| 2022-12-31 | $796.37K | -4.29% |
| 2022-09-30 | $832.10K | 80.19% |
| 2022-06-30 | $461.80K | 10.38% |
| 2022-03-31 | $418.38K | 16.03% |
| 2021-12-31 | $360.57K | -61.25% |
| 2021-09-30 | $930.45K | 293.20% |
| 2021-06-30 | $236.63K | 161.70% |
| 2021-03-31 | $90.42K | 292.79% |
| 2020-12-31 | $23.02K | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | - |
Evoke Pharma generated $1.74M in revenue during Q1 2024, up 3.55% compared to the previous quarter, and up 217.93% compared to the same period a year ago.
Evoke Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals | $5.82B | $1.39M |
| PROC | Procaps Group | $409.92M | $118.41M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DERM | Journey Medical | $79.18M | $14.86M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| CPIX | Cumberland Pharmaceuticals | $39.55M | $9.85M |
| BFRI | Biofrontera | $34.01M | $7.83M |
| AVDL | Avadel Pharmaceuticals | $27.96M | $41.50M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| JUPW | Safety Shot | $6.20M | $910.01K |
| EVOK | Evoke Pharma | $5.18M | $1.74M |
| ADMP | Adamis Pharmaceuticals | $4.76M | $9.06M |
| AKAN | Akanda | $2.16M | $762.61K |
| ACRX | Talphera | $651.00K | $117.00K |
| SHPH | Shuttle Pharmaceuticals | - | - |
| IXHL | Incannex Healthcare | - | - |
| PRFX | PainReform | - | - |
| RGC | Regencell Bioscience | - | - |
EVOK Revenue FAQ
What is Evoke Pharma’s yearly revenue?
Evoke Pharma's yearly revenue for 2023 was $5.18M, representing an increase of 106.51% compared to 2022. The company's yearly revenue for 2022 was $2.51M, representing an increase of 55.04% compared to 2021. EVOK's yearly revenue for 2021 was $1.62M, representing an increase of 6929.00% compared to 2020.
What is Evoke Pharma’s quarterly revenue?
Evoke Pharma's quarterly revenue for Q1 2024 was $1.74M, a 3.55% increase from the previous quarter (Q4 2023), and a 114.15% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.68M, a 7.24% increase from the previous quarter (Q3 2023), and a 110.45% increase year-over-year (Q4 2022). EVOK's quarterly revenue for Q3 2023 was $1.56M, a 38.14% increase from the previous quarter (Q2 2023), and a 87.82% increase year-over-year (Q3 2022).
What is Evoke Pharma’s revenue growth rate?
Evoke Pharma's revenue growth rate for the last 3 years (2021-2023) was 220.17%, and for the last 5 years (2019-2023) was 0%.